Michael-T,
I wrote an article about
it comparing it to monotherapy and other therapies. It's still experimental. It had similar cancer control and less late term toxicity compared to LDR brachy boost or HDR monotherapy. In the Taiwanese boost study they were able to achieve similar results with much less toxicity, so there are clearly a lot of variables to sort out. We don't know yet if there's any advantage over SBRT monotherapy at higher doses (like the King study at UCLA). I wouldn't think so, but we won't know until he publishes probably next year. There are several ongoing clinical trials.
SBRT boost radiation therapy in intermediate- and high-risk prostate cancer